XALKORI (crizotinib)
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·ANAPLASTIC LYMPHOMA KINASE POSITIVE NON-SMALL CELL LUNG CANCER·+3
Parke-Davis Pfizer
Indication
Anaplastic lymphoma kinase positive non-small cell lung cancer
Anaplastic lymphoma kinase-positive non-small cell lung cancer is a distinct molecular subtype of non-small cell lung cancer that affects the pulmonary epithelial tissue. Read more about Anaplastic lymphoma kinase positive non-small cell lung cancer
14 drugs 10 manufacturers
Drugs that treat it
Common Anaplastic lymphoma kinase positive non-small cell lung cancer therapies.
ZYKADIA (ceritinib)
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·ANAPLASTIC LYMPHOMA KINASE POSITIVE NON-SMALL CELL LUNG CANCER
Novartis Pharmaceuticals
ALECENSA (alectinib HCl)
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·ANAPLASTIC LYMPHOMA KINASE POSITIVE NON-SMALL CELL LUNG CANCER
GENENTECH
ALUNBRIG (brigatinib)
ANAPLASTIC LYMPHOMA KINASE POSITIVE NON-SMALL CELL LUNG CANCER
ARIAD PHARMACEU
ALUNBRIG (brigatinib)
ANAPLASTIC LYMPHOMA KINASE POSITIVE NON-SMALL CELL LUNG CANCER
Takeda Pharmaceuticals America
ALUNBRIG (brigatinib)
ANAPLASTIC LYMPHOMA KINASE POSITIVE NON-SMALL CELL LUNG CANCER
Takeda Pharmaceuticals America
ALUNBRIG (brigatinib)
ANAPLASTIC LYMPHOMA KINASE POSITIVE NON-SMALL CELL LUNG CANCER
ARIAD/TAKEDA
ALUNBRIG (brigatinib)
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·ANAPLASTIC LYMPHOMA KINASE POSITIVE NON-SMALL CELL LUNG CANCER
MILLENNIUM PHAR
ALUNBRIG (brigatinib)
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·ANAPLASTIC LYMPHOMA KINASE POSITIVE NON-SMALL CELL LUNG CANCER
MILLENNIUM PHAR
Filter & compare in the drug finder →Opens the drug finder with Anaplastic lymphoma kinase positive non-small cell lung cancer preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonAnaplastic lymphoma kinase-positive non-small cell lung cancer is a distinct molecular subtype of non-small cell lung cancer that affects the pulmonary epithelial tissue.
It is defined by chromosomal rearrangements in the *ALK* gene—most commonly a fusion with the *EML4* gene—that produce a chimeric receptor tyrosine kinase with constitutive oncogenic activity, driving unregulated cellular proliferation and survival.
Representing approximately three to five percent of non-small cell lung cancer cases, it predominantly manifests as lung adenocarcinoma and occurs disproportionately in younger adults and individuals with light or no history of tobacco use.
Clinically, these tumors frequently present at an advanced or metastatic stage, displaying a notable propensity for central nervous system involvement.
- massgeneralbrigham.org
Anaplastic lymphoma kinase-positive non-small cell lung cancer is a distinct molecular subtype of non-small cell lung cancer that affects the pulmonary epithelial tissue It is defined by chromosomal rearrangements in the *ALK* gene—most commonly a fusion with the *EML4* gene—that produce a chimeric receptor tyrosine kinase with constitutive oncogenic activity, driving unregulated cellular proliferation and survival Representing approximately three to five percent of non-small cell lung cancer ca...
- medicalnewstoday.com
Anaplastic lymphoma kinase-positive non-small cell lung cancer is a distinct molecular subtype of non-small cell lung cancer that affects the pulmonary epithelial tissue It is defined by chromosomal rearrangements in the *ALK* gene—most commonly a fusion with the *EML4* gene—that produce a chimeric receptor tyrosine kinase with constitutive oncogenic activity, driving unregulated cellular proliferation and survival
- nih.gov
It is defined by chromosomal rearrangements in the *ALK* gene—most commonly a fusion with the *EML4* gene—that produce a chimeric receptor tyrosine kinase with constitutive oncogenic activity, driving unregulated cellular proliferation and survival
- cancer.gov
It is defined by chromosomal rearrangements in the *ALK* gene—most commonly a fusion with the *EML4* gene—that produce a chimeric receptor tyrosine kinase with constitutive oncogenic activity, driving unregulated cellular proliferation and survival
- cancersupportcommunity.org
Representing approximately three to five percent of non-small cell lung cancer cases, it predominantly manifests as lung adenocarcinoma and occurs disproportionately in younger adults and individuals with light or no history of tobacco use Clinically, these tumors frequently present at an advanced or metastatic stage, displaying a notable propensity for central nervous system involvement
- cancersupportcommunity.org
Representing approximately three to five percent of non-small cell lung cancer cases, it predominantly manifests as lung adenocarcinoma and occurs disproportionately in younger adults and individuals with light or no history of tobacco use
- nih.gov
Clinically, these tumors frequently present at an advanced or metastatic stage, displaying a notable propensity for central nervous system involvement
Personalize your experience
Follow Anaplastic lymphoma kinase positive non-small cell lung cancer and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.